Investments
3Portfolio Exits
1Partners & Customers
10Service Providers
1About AbbVie
AbbVie (NYSE: ABBV) consists of scientists, researchers, communicators, manufacturing specialists, and regulatory professionals who seek to come up with new approaches to addressing today's health issues-from life-threatening illness to chronic conditions. The company focuses its R&D efforts and technology investments to pursue this goal.
AbbVie Headquarters Location
1 Waukegan Road
North Chicago, Illinois, 60064,
United States
800-255-5162
Expert Collections containing AbbVie
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find AbbVie in 4 Expert Collections, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Diabetes
1,750 items
Medical Devices
3,088 items
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Biopharma Tech
260 items
AbbVie Web Traffic
AbbVie Rank
Research containing AbbVie
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned AbbVie in 2 CB Insights research briefs, most recently on Aug 3, 2021.
Latest AbbVie News
Sep 29, 2022
TiumBio gets $4.5 million upfront from China’s Hansoh Pharmaceutical 바로가기 기자명 Kim Chan-hyuk 닫기 TiumBio said on Tuesday that it received a $4.5 million upfront payment from China’s Hansoh Pharmaceutical under the previous licensing agreement involving TU2670, a new endometriosis treatment. Earlier in August, TiumBio and Hansoh signed a $170 million deal, including a $4.5 million upfront payment, for the exclusive license to develop and commercialize TU2670 within China. “We recently completed tech transfer of TU2970, which met the condition for the short-term milestone of $1.5 million that we expect to receive early next year,” an official at TiumBio said. “The Chinese drugmaker plans to apply for a clinical trial of TU2670 next year. With Hansoh Pharmaceutical’s extensive experience of clinical development and commercialization, it will be able to release the new drug early in China.” Separately, TiumBio is conducting a phase 2a trial of TU2670 in 80 patients in five countries in Europe. The official said the company achieved about 60 percent of the patient enrollment goal and the trial was progressing smoothly. “We are discussing additional licensing deals with multiple pharmaceutical firms in North America and Europe. Once we complete the phase 2a trial in Europe, the value of a licensing deal will go up,” he said. According to TiumBio, TU2670 is an oral GnRH (Gonadotropin-releasing hormone) antagonist. The company expects the investigational drug to suppress GnRH stably with less dose than AbbVie’s Orilissa (elagolix) and improve medication convenience (once daily). In 2019, TiumBio licensed out TU2670 to Daewon Pharmaceutical, and Daewon is conducting a local phase 2 study to treat uterine fibroids.
AbbVie Investments
3 Investments
AbbVie has made 3 investments. Their latest investment was in St. Jude Children's Research Hospital as part of their Grant on December 12, 2018.
AbbVie Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/3/2018 | Grant | St. Jude Children's Research Hospital | $50M | Yes | 1 | |
6/12/2017 | Debt | |||||
5/14/2013 | Project Finance |
Date | 12/3/2018 | 6/12/2017 | 5/14/2013 |
|---|---|---|---|
Round | Grant | Debt | Project Finance |
Company | St. Jude Children's Research Hospital | ||
Amount | $50M | ||
New? | Yes | ||
Co-Investors | |||
Sources | 1 |
AbbVie Portfolio Exits
1 Portfolio Exit
AbbVie has 1 portfolio exit. Their latest portfolio exit was Carisma Therapeutics on September 21, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/21/2022 | Acq - Pending | 1 |
Date | 9/21/2022 |
|---|---|
Exit | Acq - Pending |
Companies | |
Valuation | |
Acquirer | |
Sources | 1 |
AbbVie Acquisitions
9 Acquisitions
AbbVie acquired 9 companies. Their latest acquisition was Syndesi Therapeutics on March 01, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
3/1/2022 | Series A | $24.4M | Acquired | 5 | ||
6/24/2021 | ||||||
3/2/2021 | Series A | |||||
7/15/2019 | Series A | |||||
5/25/2019 |
Date | 3/1/2022 | 6/24/2021 | 3/2/2021 | 7/15/2019 | 5/25/2019 |
|---|---|---|---|---|---|
Investment Stage | Series A | Series A | Series A | ||
Companies | |||||
Valuation | |||||
Total Funding | $24.4M | ||||
Note | Acquired | ||||
Sources | 5 |
AbbVie Partners & Customers
10 Partners and customers
AbbVie has 10 strategic partners and customers. AbbVie recently partnered with iSTAR Medical on July 7, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/20/2022 | Partner | Belgium | AbbVie, iSTAR enter alliance to support MINIject MIGS device AbbVie and iSTAR Medical have entered into a strategic alliance to develop and commercialize the MINIject minimally invasive glaucoma surgical device for patients with glaucoma , according to a press release . | 2 | |
7/13/2022 | Partner | United States | CytomX Therapeutics Provides Strategic Update CX-2029 is part of CytomX Therapeutics , Inc. 's partnership with AbbVie . | 1 | |
7/8/2022 | Partner | United States | AbbVie dumps an early-stage drug in $225M Alzheimer's alliance with Alector Back in November , as Biogen and the controversy surrounding Aduhelm soaked up the attention around Alzheimer 's R&D , Alector quietly presented Phase I data for an AbbVie-partnered program at the annual conference for Clinical Trials on Alzheimer 's Disease . | 2 | |
7/8/2022 | Partner | ||||
6/22/2022 | Partner |
Date | 7/20/2022 | 7/13/2022 | 7/8/2022 | 7/8/2022 | 6/22/2022 |
|---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | Belgium | United States | United States | ||
News Snippet | AbbVie, iSTAR enter alliance to support MINIject MIGS device AbbVie and iSTAR Medical have entered into a strategic alliance to develop and commercialize the MINIject minimally invasive glaucoma surgical device for patients with glaucoma , according to a press release . | CytomX Therapeutics Provides Strategic Update CX-2029 is part of CytomX Therapeutics , Inc. 's partnership with AbbVie . | AbbVie dumps an early-stage drug in $225M Alzheimer's alliance with Alector Back in November , as Biogen and the controversy surrounding Aduhelm soaked up the attention around Alzheimer 's R&D , Alector quietly presented Phase I data for an AbbVie-partnered program at the annual conference for Clinical Trials on Alzheimer 's Disease . | ||
Sources | 2 | 1 | 2 |
AbbVie Service Providers
1 Service Provider
AbbVie has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor |
Service Provider | |
|---|---|
Associated Rounds | Acq - P2P |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
AbbVie Team
34 Team Members
AbbVie has 34 team members, including current Chief Executive Officer, Richard A. Gonzalez.
Name | Work History | Title | Status |
|---|---|---|---|
Richard A. Gonzalez | Chief Executive Officer | Current | |
Name | Richard A. Gonzalez | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer | ||||
Status | Current |
You May Also Like
Pfizer (NYSE: PFE) offers a diversified health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. It works across various markets to promote wellness, prevention, treatments, and cures that challenge feared diseases. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. The company was founded in 1849 and is based in New York, New York.
athenahealth offers billing, practice management, and EHR services. athenahealth's offering is a web-based software, rules database offered as a subscription to physicians that combines in-office practice management functionality with a billing service. It is based in Watertown, Massachusetts.
Limbix makes virtual reality and digital treatment tools for therapists.
Atentiv is committed to delivering the promise of new cognitive skills for millions of children around the world so that they can achieve success in school, at home and in life. By working as a team, in partnership with educators and clinicians, the company seeks to drive transformative change in education and many other areas of unmet educational and clinical need. The ATENTIVmynd Games is a product platform of personalized digital learning tools that uses an individual's unique 'cognitive signature' of brain wave activity to measure, train and manage multiple cognitive function development that significantly improve attention and impulse control.
Virta Health develops a clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery.
SYNAPS Dx focuses on the research, development, and commercialization of diagnostics for neurodegenerative disorders and conditions such as Alzheimer's Disease.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.